Xia Yu

机构：Shanghai Jiao Tong University, TCL (China), XinHua Hospital, AbbVie (United States), The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing Medical University · ORCID：0000-0001-5078-7962

发表论文 39 篇 · 总被引 281 次 · h-index 9

代表论文

• Precise exposure assessment revealed the cancer risk and disease burden caused by trihalomethanes and haloacetic acids in Shanghai indoor swimming pool water (2019 · Journal of Hazardous Materials · 被引 35)
• Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer (2025 · Gynecologic Oncology · 被引 13)
• An excellent response to topical therapy of four congenital hemidysplasia with ichthyosiform erythroderma and limb defects syndrome patients with an increased concentration of simvastatin ointment (2019 · Journal of the European Academy of Dermatology and Venereology · 被引 10)
• Comparison of Jinzhen oral liquid and ambroxol hydrochloride and clenbuterol hydrochloride oral solution in the treatment of acute bronchitis in children: A multicenter, non-inferiority, prospective, randomized controlled trial (2024 · Acta Pharmaceutica Sinica B · 被引 8)
• Clinical efficacy and safety of targeted injection of PRP with skin booster in the treatment of aging face (2023 · Biotechnology and Genetic Engineering Reviews · 被引 8)
• 1348 Final overall survival analysis of HARMONi-A study comparing ivonescimab plus chemotherapy to chemotherapy alone in patients with EGFR + NSCLC progressed on EGFR-TKI treatment (2025 · 被引 7)